Published April 15, 2015 | Version v1
Journal article

A retrospective study of the prognostic value of MRI-derived residual tumors at the end of intensity-modulated radiotherapy in 358 patients with locally-advanced nasopharyngeal carcinoma

  • 1. Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, No. 87, Xiangya Road, Changsha, Hunan Province 410008 P.R. (China)

Description

To retrospectively analyze the prognostic value of magnetic resonance imaging (MRI)-derived residual tumors after intensity-modulated radiation therapy (IMRT) in the patients with locally-advanced nasopharyngeal carcinoma. A total of 358 patients with locally-advanced nasopharyngeal carcinoma who received IMRT were classified as having residual tumors or no residual tumor based on MRI at the end of radiotherapy. The χ2 test, log-rank test, Cox proportional hazards regression model and Kaplan-Meir survival curves were used to investigate the relationship of clinicopathological features and residual tumors and to assess the prognostic value of residual tumors. The 3-year overall survival (OS) rate was 73% in the residual tumor group and 90% in the no residual tumor group (HR 2.15, 95% CI 1.21-3.82,, P = 0.007); 3-year local relapse-free survival (LRFS) was 89% in the residual tumor group and 97% in the no residual tumor group (HR 4.46, 95% CI 1.61-12.38, P = 0.002); 3-year disease free survival (DFS) was 67% in the residual tumor group and 82% in the no residual tumor group (HR 2.21, 95% CI 1.40-3.48, P = 0.001). A high prescribed radiation dose (>73.92 Gy) did not increase the percentage volume of the GTVnx receiving 95% of the prescribed dose (GTVnx V95%) or improve any survival outcome. The presence of a residual tumor after IMRT was a significant negative independent prognostic factor for OS, LRFS and DFS. Although IMRT have improved the distribution of radiotherapy doses into the tumors, residual tumors detected by MRI after IMRT are still associated with poor prognosis in patients with advanced nasopharyngeal carcinoma

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-015-0401-0; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464998

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
10
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47070000
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; GY RANGE 10-100; NMR IMAGING; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SURVIVAL CURVES
Descriptors DEC
ABSORBED DOSE RANGE; DIAGNOSTIC TECHNIQUES; DISEASES; DOSES; GY RANGE; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIATION DOSE RANGES; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) He et al.
Notes
PMCID: PMC4464998; PMID: 25881159; PUBLISHER-ID: 401; OAI: oai:pubmedcentral.nih.gov:4464998; licensee BioMed Central. 2015